EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Mathurin Fumery  ¹     Antoine Defrance  ²     Xavier Roblin  ³     Carmen Stefanescu  ⁴     Bénédicte Caron  ⁵     Xavier Hebuterne  ⁶     Romain Altwegg  ⁷     Catherine Leberre  ⁸     Maria Nachury  ⁹     Antoine Meyer  ¹⁰     Philippe Ah Soune  ¹¹     Cyrielle Gilletta De Saint Joseph  ¹²     Nicolas DUVEAU  ¹³     Mathieu Uzzan  ¹⁴     Amelie Biron  ¹⁵     David Laharie  ¹⁶     Stephane NANCEY  ¹⁷     My-Linh Tran-Minh  ¹⁸     Ludovic Caillo  ¹⁹     Thierry Paupard  ²⁰     Yasmine Elgharabawy     Laurent Peyrin-Biroulet  ^21    
1 Amiens University Hospital, Amiens, France
² GETAID, Paris, France
³ University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, France
⁴ Hopital Beaujon, Clichy, France
⁵ CHU Nancy, Nancy, France
⁶ Hospital Archet 2, Nice, Nice, France
⁷ Hopital Saint Eloi Hepatologie Gastro Enterologie, Montpellier, France
⁸ CHU Nantes, Nantes, France
⁹ CHRU Lille, Courbevoie Cedex, France
¹⁰ Hôpital Bicêtre, Bicetre, France
¹¹ CH Toulon, Toulon, France
¹² Hopital Rangueil, Toulouse, France
¹³ CH Roubaix, Roubaix Cedex 1, France
¹⁴ Hôpital Mondor, Paris, France
¹⁵ CHU Reims, Reims, France
¹⁶ CHU de Bordeaux, Pessac cedex, France
¹⁷ CHU Lyon, Pierre Benite, France
¹⁸ Hopital Saint-Louis, Paris, France
¹⁹ CHU de Nimes, Nîmes, France
²⁰ CH Dunkerque, Dunkerque, France
²¹ Nancy University Hospital, Vandoeuvre-les-Nancy, France

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)